With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO Neil Closner also highlights MedReleaf’s important efforts in conducting R&D and clinical studies in order to present practitioners with relevant data demonstrating the benefits of medical cannabis.
Coming from a hospital background, what was your personal motivation behind founding a medicinal cannabis company in 2013?
"No other country has grown cannabis at an industrial level before and we are well positioned to both develop and export best practices globally. We have learned to scale production and have found new and innovative ways to render production more efficient."
